In a Phase I clinical trial, GM-CT-01, a galectin-1 and -3 inhibitor, is being tested with and without 5-fluorouracil in patients with advanced-stage solid tumor cancers, including breast cancer to study the effects of galectin inhibitors on disease progression and their ability to improve the chemotherapy response in patients who have not responded well to previous treatments [19]. The gene discussed is LGALS1; the disease is breast carcinoma.